One of the top stories of this past year was the FDA's approval of the novel weight loss drugs Belviq and Qysmia. As most of us Americans are aware, obesity is increasingly becoming the public health epidemic of our time. We are often bombarded with news stories and reality television shows highlighting average Americans struggling with their weight and attempting to regain control over their lives. These new drugs might finally offer hope for these individuals. The FDA's decision to approve Belviq and Qysmia brings to an end a thirteen year dry spell during which no new obesity drugs were approved in the United States. The launch of these two therapies will have a profound impact on the lives of obese patients and on the obesity market as a whole. According to our analyst's updated market outlook, the sales of the obesity market are expected to increase six-fold to over $2 billion by 2021i, assuming that current reimbursement policies remain the same.  In an industry experiencing modest growth, major setbacks in patent losses and uncertainty about the U.S. healthcare market, the obesity market is one area in pharma that we expect to see consistently robust growth.

Naomi Inoshita is an Associate with the DRG Consulting group.

iPharmacor: Obesity, 2012

DRG becomes Clarivate

View Now